33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunotherapy for non-small cell lung cancers (NSCLC) with oncogenic driver mutations: New results from the global IMMUNOTARGET registry
    Meeting Abstract

    Gautschi, O.; Drilon, A.; Milia, J.; Lusque, A.; Mhanna, L.; Li, B.; Sabari, J.; Cortot, A.; Besse, B.; Mezquita, L.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
    Meeting Abstract

    Jomenez Alguilar, E.; Gainor, J.; Kravets, S.; Khosrowjerdi, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Rizvi, H.; Hellmann, M.; Awad, M.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET fusion+ non-small cell lung cancer
    Meeting Abstract

    Oxnard, G.; Subbiah, V.; Park, K.; Bauer, T.; Wirth, L.; Velcheti, V.; Shah, M.; Besse, B.; Boni, V.; Reckamp, K.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer
    Meeting Abstract

    Drilon, A.; Clark, J.; Weiss, J.; Ou, S.; Camidge, D. R.; Solomon, B.; Otterson, G.; Villaruz, L.; Riely, G.; Heist, R.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Toxicity and local control in "ultra-central" lung tumors treated with SBRT or high-dose hypofractionated RT
    Meeting Abstract

    Wang, C.; Sidiqi, B.; Yorke, E.; McKnight, D.; Dick-Godfrey, R.; Torres, D.; Gelblum, D.; Rimner, A.; Wu, A.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Histologic subtyping in pathologic stage I lung adenocarcinoma provides risk-based stratification for surveillance
    Meeting Abstract

    Takahashi, Y.; Eguchi, T.; Kameda, K.; Lu, S.; Vaghjiani, R.; Tan, K. S.; Jones, D.; Travis, W.; Adusumilli, P.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti-PD-(L) 1 therapy
    Meeting Abstract

    Hellmann, M.; Jänne, P.; Opyrchal, M.; Hafez, N.; Raez, L.; Gabrilovich, D.; Wang, F.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Phase II data for the MET inhibitor tepotinib in patients with advanced NSCLC and MET exon 14-skipping mutations
    Meeting Abstract

    Felip, E.; Sakai, H.; Patel, J.; Horn, L.; Veillon, R.; Griesinger, F.; Bruns, R.; Scheele, J.; Paik, P.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer
    Meeting Abstract

    Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.; Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Three-dimensional immunofluorescence analysis of dynamic vessel co-option of spread through air spaces (STAS) in lung cancer
    Meeting Abstract

    Yagi, Y.; Aly, R.; Tabata, K.; Rekhtman, N.; Eguchi, T.; Montecalvo, J.; Manova, K.; Adusumilli, P.; Hameed, M.; Travis, W.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save